尿神经生长因子受体 p75 细胞外结构域作为中国人队列肌萎缩侧索硬化症的生物标志物。
Urinary Extracellular Domain of Neurotrophin Receptor p75 as a Biomarker for Amyotrophic Lateral Sclerosis in a Chinese cohort.
机构信息
Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China.
Department of Human Physiology and Centre for Neuroscience, Flinders University, Adelaide, South Australia, Australia.
出版信息
Sci Rep. 2017 Jul 11;7(1):5127. doi: 10.1038/s41598-017-05430-w.
To comprehensively assess whether p75 in urine could be a candidate biomarker for ALS evaluation. Urine samples were collected from 101 ALS patients, 108 patients with other neurological disease (OND) and 97 healthy controls. 61 ALS patients were followed up with clinical data including ALSFRS-r every 6 to 12 months, 23 ALS patients died and 17 ALS patients lost touch during follow up period. Enzyme-linked immunoassay was employed to determine urine p75 concentration. The ALSFRS-r was employed to assess the severity of ALS. The concentration of p75 in ALS was significantly higher than that of OND and CTRL (p < 0.001). Additionally, urine p75 concentrations in ALS-definite grade patients were significantly higher than that in ALS-probable grade and ALS-possible grade patients (p < 0.001). Higher urine p75 concentrations were correlated with increased clinical stage (p = 0.0309); urine p75 concentrations and ALSFRS-r were negatively correlated (p = 0.022); and urine p75 concentration in the fast-progressing ALS group was significantly higher than that in slow-progression (p = 0.0026). Our finding indicates that urine p75 concentration provides additional evidence for patients with clinically suspected ALS, and can be employed to evaluate ALS-severity.
为了全面评估尿液中的 p75 是否可以作为 ALS 评估的候选生物标志物。收集了 101 名 ALS 患者、108 名其他神经疾病（OND）患者和 97 名健康对照者的尿液样本。61 名 ALS 患者接受了临床数据的随访，包括每 6-12 个月的 ALSFRS-r，23 名 ALS 患者在随访期间死亡，17 名 ALS 患者失去联系。采用酶联免疫吸附法测定尿液 p75 浓度。使用 ALSFRS-r 评估 ALS 的严重程度。ALS 患者的 p75 浓度明显高于 OND 和 CTRL 患者（p<0.001）。此外，ALS 确诊级患者的尿 p75 浓度明显高于 ALS 可能级和 ALS 可疑级患者（p<0.001）。较高的尿 p75 浓度与临床分期增加相关（p=0.0309）；尿 p75 浓度与 ALSFRS-r 呈负相关（p=0.022）；快速进展性 ALS 组的尿 p75 浓度明显高于缓慢进展性 ALS 组（p=0.0026）。我们的研究结果表明，尿 p75 浓度为临床上疑似 ALS 的患者提供了额外的证据，可用于评估 ALS 的严重程度。
Zotero 插件